A Swedish company’s combination gel and pump delivery system, Lecigon, has received regulatory approval for the treatment of patients with advanced Parkinson’s disease.
Ahead of the CPhI Worldwide in Madrid next week, Nemaura announced that it would be showcasing its newly developed 48-hour diclofenac transdermal patch and would be linking up with an unnamed global pharma company to develop three new products.
As previously reported, researchers have determined that ketamine has potential as a treatment for patients at imminent risk for suicide, and as a therapy for treatment-resistant depression.
In this first part of a two-part investigation, we look at how NDMA receptor antagonists, such as ketamine, could be poised to make a breakthrough in the treatment of depression – an area where the pharma industry has struggled to identify new targets...
A study at Washington University in St. Louis has shown a new way to deliver drugs to the brainstem in a non-invasive administration: microbubbles and ultrasound.
Impel Neuropharma announced the first participant have been dosed in a Phase I trial looking at safety and tolerability for the company’s intranasal olanzapine product.
Researchers from the Clinic for Special Children have developed a drug delivery catheter system that could reach a larger population of patients receive Biogen’s Spinraza treatment.
Lexaira Bioscience says its DehydraTECH platform has demonstrated significant improvements to the bioavailability of cannabinoids, and could be applied to other pharmaceuticals.
Frequency Therapeutics initiates a Phase I/II clinical trial for hearing restoration, using progenitor cell activator technology for the first time in adult patients.
